Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)

Myeloma Clinical Trial

— CHIME  

Official title:

Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06007989
• Other study ID #: CFTsp212
• Status: Not yet recruiting
• Start date: November 1, 2023
• Est. completion date: August 1, 2024

Study information

• Verified date: August 2023
• Source: The Christie NHS Foundation Trust
• Contact: Adam Jones, MBBS, MSc, MRCP
• Phone: +44 161 276 1234
• Email: adam.jones35[@]nhs.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study is looking at how myeloma is related to low oxygen levels (hypoxia) in the bone marrow. This is to understand the disease better. It might also guide treatment in the future. For the study, we will run tests on a portion of the samples taken during a bone marrow biopsy. A bone marrow biopsy is taken as part of the diagnosis or follow up of myeloma. The tests in our study will look closely at the make-up of immune cells in the bone marrow, highlight areas of low oxygen, and look at genetic changes in cells from low-oxygen areas. We will ask patients to take a capsule the day before their bone marrow biopsy containing pimonidazole hydrochloride, a substance which will show up areas of low oxygen on tests. Overall we want to know: 1. If myeloma cells 'live' in areas of low oxygen in the bone marrow 2. What are the immune and bone marrow cells which are neighbours of myeloma cells? 3. Are there genetic changes in low oxygen myeloma cells For the pilot study, we want to know: 4. Can we use new techniques to study questions 1-3? The techniques we want to use are pimonidazole with multiplex immunohistochemistry and single cell RNA sequencing. The information we get from the tests will help us get a better understanding of how myeloma works. Future studies may also use these results to develop new kinds of drugs for myeloma.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10
• Est. completion date: August 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Male or female patients referred to The Christie NHS Foundation Trust from another hospital with proven multiple myeloma which may be either treatment naïve or previously treated.

2. Aged 18 or over 3. World Health Organisation (WHO) performance status 0 to 2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks 4. Provision of written informed consent 5. Willing to undergo a bone marrow biopsy 6. Willing to take pimonidazole hydrochloride

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study (applies to staff at the study site)

2. Evidence of any significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study

3. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Related Conditions & MeSH terms

• Hypoxia
• Multiple Myeloma
• Myeloma
• Neoplasms, Plasma Cell

Locations

Country	Name	City	State
United Kingdom	The Christie NHS Foundation Trust	Manchester	Greater Manchester

Sponsors (1)

Lead Sponsor	Collaborator
The Christie NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Qualitative assessment of the utility of a set of investigational tools for investigating the bone marrow microenvironment in myeloma patients	Specifically we aim to determine the feasibility of using pimonidazole as a marker of hypoxia in conjunction with: A) Multiplex immunohistochemistry to characterise the spatial organization of cellular inflammatory elements and myeloma cells in the bone marrow, B)Single cell RNA sequencing to characterise the expression profile of myeloma cells in hypoxic areas of marrow	Assessment is at the time of diagnosis.